MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,818.93
+0.58%
NASDAQ 100
$31,224.47
+0.48%
DOW JONES
$51,521.00
+0.49%
NASDAQ Composite
$27,599.79
+0.45%
RUSSELL 2000
$2,813.40
-0.72%
CBOE VIX
$15.01
-3.29%
Sector Heatmap
Technology+0.53%
Financials+0.24%
Healthcare-0.17%
Consumer Cycl+1.20%
Consumer Staples+0.90%
Energy+0.47%
Industrials+0.87%
Materials+0.46%
Real Estate+1.06%
Utilities+2.98%
Comm Services+0.04%
NERV — Minerva Neurosciences, Inc
NasdaqMinerva Neurosciences, Inc
$3.43
+0.11(+3.31%)
- O
- 3.38
- H
- 3.49
- L
- 3.28
- V
- 103.57K
⏱️ End-of-day dataAs of Oct 6, 2026
Chart
About NERV
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJul 1, 2014
Employees7
Stock ExchangeNasdaq
Ticker SymbolNERV
Key Financial Statistics
| Market Cap | $156.61M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $2.12 - $12.46 |
| 52-Week Avg Volume | 908.2K |
| VWAP | $3.42 |
| Transactions | 2,037 |
| Total Recorded Bars | 3,085 days |